- Home
- LSPD vs IMCR Comparison
LSPD vs IMCR Comparison
Compare LSPD & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSPD
- IMCR
- Stock Information
- Founded
- LSPD 2005
- IMCR 2008
- Country
- LSPD Canada
- IMCR United Kingdom
- Employees
- LSPD N/A
- IMCR N/A
- Industry
- LSPD
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSPD
- IMCR Health Care
- Exchange
- LSPD Nasdaq
- IMCR Nasdaq
- Market Cap
- LSPD 1.7B
- IMCR 1.8B
- IPO Year
- LSPD 2020
- IMCR 2021
- Fundamental
- Price
- LSPD $12.36
- IMCR $33.81
- Analyst Decision
- LSPD Buy
- IMCR Buy
- Analyst Count
- LSPD 13
- IMCR 8
- Target Price
- LSPD $14.19
- IMCR $57.00
- AVG Volume (30 Days)
- LSPD 458.1K
- IMCR 270.5K
- Earning Date
- LSPD 11-06-2025
- IMCR 11-05-2025
- Dividend Yield
- LSPD N/A
- IMCR N/A
- EPS Growth
- LSPD N/A
- IMCR N/A
- EPS
- LSPD N/A
- IMCR N/A
- Revenue
- LSPD $1,115,677,000.00
- IMCR $356,145,000.00
- Revenue This Year
- LSPD $14.32
- IMCR $31.83
- Revenue Next Year
- LSPD $11.94
- IMCR $8.50
- P/E Ratio
- LSPD N/A
- IMCR N/A
- Revenue Growth
- LSPD 15.46
- IMCR 26.78
- 52 Week Low
- LSPD $7.34
- IMCR $23.15
- 52 Week High
- LSPD $18.96
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- LSPD 54.42
- IMCR 46.61
- Support Level
- LSPD $11.66
- IMCR $35.33
- Resistance Level
- LSPD $12.23
- IMCR $36.76
- Average True Range (ATR)
- LSPD 0.30
- IMCR 1.43
- MACD
- LSPD 0.02
- IMCR 0.00
- Stochastic Oscillator
- LSPD 82.74
- IMCR 30.79
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.